1887

Abstract

As respiratory syncytial virus (RSV) targets the mucosal surfaces of the respiratory tract, induction of both systemic and mucosal immunity will be critical for optimal protection. In this study, the ability of an intranasally delivered, formalin-inactivated bovine RSV (FI-BRSV) vaccine co-formulated with CpG oligodeoxynucleotides (ODN) and polyphosphazenes (PP) to induce systemic and mucosal immunity, as well as protection from BRSV challenge, was evaluated. Intranasal immunization of mice with FI-BRSV formulated with CpG ODN and PP resulted in both humoral and cell-mediated immunity, characterized by enhanced production of BRSV-specific serum IgG, as well as increased gamma interferon and decreased interleukin-5 production by -restimulated splenocytes. These mice also developed mucosal immune responses, as was evident from increased production of BRSV-specific IgG and IgA in lung-fragment cultures. Indeed, the increases in serum and mucosal IgG, and in particular mucosal IgA and virus-neutralizing antibodies, were the most critical differences observed between FI-BRSV formulated with both CpG ODN and PP in comparison to formulations with CpG ODN, non-CpG ODN or PP individually. Finally, FI-BRSV/CpG/PP was the only formulation that resulted in a significant reduction in viral replication upon BRSV challenge. Co-formulation of CpG ODN and PP is a promising new vaccine platform technology that may have applications in mucosal immunization in humans.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.83300-0
2008-01-01
2019-11-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/89/1/250.html?itemId=/content/journal/jgv/10.1099/vir.0.83300-0&mimeType=html&fmt=ahah

References

  1. Almeida, R. S., Domingues, H. G., Coswig, L. T., D'Arce, R. C., de Carvalho, R. F. & Arns, C. W. ( 2004; ). Detection of bovine respiratory syncytial virus in experimentally infected balb/c mice. Vet Res 35, 189–197.[CrossRef]
    [Google Scholar]
  2. Andrianov, A. K., Svirkin, Y. Y. & LeGolvan, M. P. ( 2004; ). Synthesis and biologically relevant properties of polyphosphazene polyacids. Biomacromolecules 5, 1999–2006.[CrossRef]
    [Google Scholar]
  3. Baca-Estrada, M. E., Snider, M., Tikoo, S. K., Harland, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 1996; ). Immunogenicity of bovine herpesvirus 1 glycoprotein D in mice: effect of antigen form on the induction of cellular and humoral immune responses. Viral Immunol 9, 11–22.[CrossRef]
    [Google Scholar]
  4. Ballas, Z. K., Rasmussen, W. L. & Krieg, A. M. ( 1996; ). Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol 157, 1840–1845.
    [Google Scholar]
  5. Cano, F., Plotnicky-Gilquin, H., Nguyen, T. N., Liljeqvist, S., Samuelson, P., Bonnefoy, J., Stahl, S. & Robert, A. ( 2000; ). Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine 18, 2743–2752.[CrossRef]
    [Google Scholar]
  6. Chin, J., Magoffin, R. L., Shearer, L. A., Schieble, J. H. & Lennette, E. H. ( 1969; ). Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89, 449–463.
    [Google Scholar]
  7. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V. & Harding, C. V. ( 1997; ). CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 186, 1623–1631.[CrossRef]
    [Google Scholar]
  8. Connors, M., Kulkarni, A. B., Firestone, C. Y., Holmes, K. L., Morse, H. C., III, Sotnikov, A. V. & Murphy, B. R. ( 1992; ). Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 66, 7444–7451.
    [Google Scholar]
  9. Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C. Y., Morse, H. C., III & Murphy, B. R. ( 1994; ). Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 68, 5321–5325.
    [Google Scholar]
  10. Corpet, F. ( 1988; ). Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 16, 10881–10890.[CrossRef]
    [Google Scholar]
  11. Davis, H. L., Weeratna, R., Waldschmidt, T. J., Tygrett, L., Schorr, J. & Krieg, A. M. ( 1998; ). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol 160, 870–876.
    [Google Scholar]
  12. Dumais, N., Patrick, A., Moss, R. B., Davis, H. L. & Rosenthal, K. L. ( 2002; ). Mucosal immunization with inactivated human immunodeficiency virus plus CpG oligodeoxynucleotides induces genital immune responses and protection against intravaginal challenge. J Infect Dis 186, 1098–1105.[CrossRef]
    [Google Scholar]
  13. Etchart, N., Baaten, B., Andersen, S. R., Hyland, L., Wong, S. Y. & Hou, S. ( 2006; ). Intranasal immunisation with inactivated RSV and bacterial adjuvants induces mucosal protection and abrogates eosinophilia upon challenge. Eur J Immunol 36, 1136–1144.[CrossRef]
    [Google Scholar]
  14. Falcone, V., Mihm, D., Neumann-Haefelin, D., Costa, C., Nguyen, T., Pozzi, G. & Ricci, S. ( 2006; ). Systemic and mucosal immunity to respiratory syncytial virus induced by recombinant Streptococcus gordonii surface-displaying a domain of viral glycoprotein G. FEMS Immunol Med Microbiol 48, 116–122.[CrossRef]
    [Google Scholar]
  15. Fulginiti, V. A., Eller, J. J., Sieber, O. F., Joyner, J. W., Minamitani, M. & Meiklejohn, G. ( 1969; ). Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89, 435–448.
    [Google Scholar]
  16. Gallichan, W. S., Woolstencroft, R. N., Guarasci, T., McCluskie, M. J., Davis, H. L. & Rosenthal, K. L. ( 2001; ). Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 166, 3451–3457.[CrossRef]
    [Google Scholar]
  17. Hartmann, G. & Krieg, A. M. ( 2000; ). Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol 164, 944–953.[CrossRef]
    [Google Scholar]
  18. Hartmann, G., Weeratna, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D. & other authors ( 2000; ). Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol 164, 1617–1624.[CrossRef]
    [Google Scholar]
  19. Heilman, C. A. ( 1990; ). From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 161, 402–406.[CrossRef]
    [Google Scholar]
  20. Ioannou, X. P., Gomis, S. M., Karvonen, B., Hecker, R., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2002; ). CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein. Vaccine 21, 127–137.[CrossRef]
    [Google Scholar]
  21. Jakob, T., Walker, P. S., Krieg, A. M., Udey, M. C. & Vogel, J. C. ( 1998; ). Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol 161, 3042–3049.
    [Google Scholar]
  22. Kahn, J. S., Roberts, A., Weibel, C., Buonocore, L. & Rose, J. K. ( 2001; ). Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol 75, 11079–11087.[CrossRef]
    [Google Scholar]
  23. Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. & Parrott, R. H. ( 1969; ). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89, 422–434.
    [Google Scholar]
  24. Leader, S. & Kohlhase, K. ( 2003; ). Recent trends in severe respiratory syncytial virus (RSV) among US infants, 1997 to 2000. J Pediatr 143, S127–S132.
    [Google Scholar]
  25. Logan, A. C., Chow, K. P., George, A., Weinstein, P. D. & Cebra, J. J. ( 1991; ). Use of Peyer's patch and lymph node fragment cultures to compare local immune responses to Morganella morganii. Infect Immun 59, 1024–1031.
    [Google Scholar]
  26. Mapletoft, J. W., Oumouna, M., Townsend, H. G., Gomis, S., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2006; ). Formulation with CpG oligodeoxynucleotides increases cellular immunity and protection induced by vaccination of calves with formalin-inactivated bovine respiratory syncytial virus. Virology 353, 316–323.[CrossRef]
    [Google Scholar]
  27. Matsuoka, T., Okamoto, Y., Matsuzaki, Z., Endo, S., Ito, E., Tsutsumi, H., Williamson, R. A., Sakurai, H., Burton, D. R. & Saito, I. ( 2002; ). Characteristics of immunity induced by viral antigen or conferred by antibody via different administration routes. Clin Exp Immunol 130, 386–392.[CrossRef]
    [Google Scholar]
  28. McCluskie, M. J. & Davis, H. L. ( 1998; ). CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 161, 4463–4466.
    [Google Scholar]
  29. McCluskie, M. J. & Davis, H. L. ( 2000; ). Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants. Vaccine 19, 413–422.[CrossRef]
    [Google Scholar]
  30. McNeal, M. M., Rae, M. N. & Ward, R. L. ( 1999; ). Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus. Vaccine 17, 1573–1580.[CrossRef]
    [Google Scholar]
  31. Mutwiri, G., Benjamin, P., Soita, H., Townsend, H., Yost, R., Roberts, B., Andrianov, A. K. & Babiuk, L. A. ( 2007; ). Poly[di(sodium carboxylatoethylphenoxy)phosphazene] (PCEP) is a potent enhancer of mixed Th1/Th2 immune responses in mice immunized with influenza virus antigens. Vaccine 25, 1204–1213.[CrossRef]
    [Google Scholar]
  32. Openshaw, P. J., Clarke, S. L. & Record, F. M. ( 1992; ). Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 4, 493–500.[CrossRef]
    [Google Scholar]
  33. Oumouna, M., Mapletoft, J. W., Karvonen, B. C., Babiuk, L. A. & van Drunen Littel-van den Hurk, S. ( 2005; ). Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79, 2024–2032.[CrossRef]
    [Google Scholar]
  34. Paramore, L. C., Ciuryla, V., Ciesla, G. & Liu, L. ( 2004; ). Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22, 275–284.[CrossRef]
    [Google Scholar]
  35. Payne, L. G. & Andrianov, A. K. ( 1998; ). Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31, 185–196.[CrossRef]
    [Google Scholar]
  36. Payne, L. G., Jenkins, S. A., Andrianov, A. & Roberts, B. E. ( 1995; ). Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 6, 473–493.
    [Google Scholar]
  37. Payne, L. G., Jenkins, S. A., Woods, A. L., Grund, E. M., Geribo, W. E., Loebelenz, J. R., Andrianov, A. K. & Roberts, B. E. ( 1998; ). Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16, 92–98.[CrossRef]
    [Google Scholar]
  38. Philippou, S., Otto, P., Reinhold, P., Elschner, M. & Streckert, H. J. ( 2000; ). Respiratory syncytial virus-induced chronic bronchiolitis in experimentally infected calves. Virchows Arch 436, 617–621.[CrossRef]
    [Google Scholar]
  39. Prince, G. A., Mond, J. J., Porter, D. D., Yim, K. C., Lan, S. J. & Klinman, D. M. ( 2003; ). Immunoprotective activity and safety of a respiratory syncytial virus vaccine: mucosal delivery of fusion glycoprotein with a CpG oligodeoxynucleotide adjuvant. J Virol 77, 13156–13160.[CrossRef]
    [Google Scholar]
  40. Roberts, T. L., Sweet, M. J., Hume, D. A. & Stacey, K. J. ( 2005; ). Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. J Immunol 174, 605–608.[CrossRef]
    [Google Scholar]
  41. Stott, E. J. & Taylor, G. ( 1985; ). Respiratory syncytial virus. Brief review. Arch Virol 84, 1–52.
    [Google Scholar]
  42. Stott, E. J., Ball, L. A., Young, K. K., Furze, J. & Wertz, G. W. ( 1986; ). Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge. J Virol 60, 607–613.
    [Google Scholar]
  43. Stott, E. J., Taylor, G., Ball, L. A., Anderson, K., Young, K. K., King, A. M. & Wertz, G. W. ( 1987; ). Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 61, 3855–3861.
    [Google Scholar]
  44. Tebbey, P. W., Unczur, C. A., LaPierre, N. A. & Hancock, G. E. ( 1999; ). A novel and effective intranasal immunization strategy for respiratory syncytial virus. Viral Immunol 12, 41–45.[CrossRef]
    [Google Scholar]
  45. Tebbey, P. W., Scheuer, C. A., Peek, J. A., Zhu, D., LaPierre, N. A., Green, B. A., Phillips, E. D., Ibraghimov, A. R., Eldridge, J. H. & Hancock, G. E. ( 2000; ). Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H. Vaccine 18, 2723–2734.[CrossRef]
    [Google Scholar]
  46. Teloni, R., von Hunolstein, C., Mariotti, S., Donati, S., Orefici, G. & Nisini, R. ( 2004; ). Antibody classes & subclasses induced by mucosal immunization of mice with Streptococcus pyogenes M6 protein & oligodeoxynucleotides containing CpG motifs. Indian J Med Res 119 (Suppl.), 126–130.
    [Google Scholar]
  47. Vollmer, J., Janosch, A., Laucht, M., Ballas, Z. K., Schetter, C. & Krieg, A. M. ( 2002; ). Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev 12, 165–175.[CrossRef]
    [Google Scholar]
  48. Walsh, E. E. ( 1993; ). Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice. Vaccine 11, 1135–1138.[CrossRef]
    [Google Scholar]
  49. Waris, M. E., Tsou, C., Erdman, D. D., Zaki, S. R. & Anderson, L. J. ( 1996; ). Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 70, 2852–2860.
    [Google Scholar]
  50. Waris, M. E., Tsou, C., Erdman, D. D., Day, D. B. & Anderson, L. J. ( 1997; ). Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV. J Virol 71, 6935–6939.
    [Google Scholar]
  51. Weibel, R. E., Stokes, J., Jr, Leagus, M. B., Mascoli, C. C. & Hilleman, M. R. ( 1966; ). Respiratory virus vaccines. V. Field evaluation for efficacy of heptavalent vaccine. Am Rev Respir Dis 94, 362–379.
    [Google Scholar]
  52. Wu, J. Y., Wade, W. F. & Taylor, R. K. ( 2001; ). Evaluation of cholera vaccines formulated with toxin-coregulated pilin peptide plus polymer adjuvant in mice. Infect Immun 69, 7695–7702.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.83300-0
Loading
/content/journal/jgv/10.1099/vir.0.83300-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error